Biofrontera Inc.
BFRI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -22.6% | 5.1% | -31.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.5% | 73.6% | 64.2% | 58% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -89.8% | -56.2% | -52.9% | -13.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -95.1% | -59% | -48.9% | -11.1% |
| EPS | -0.62 | -0.57 | -0.76 | 2.97 |
| % Growth | -8.8% | 25% | -125.6% | – |
| EPS Diluted | -0.62 | -0.57 | -0.76 | 2.97 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -90.6% | -55% | -45% | -8.9% |